Is Cannabis Legal in Germany?

Medical Cannabis in Germany

Germany has operated one of Europe's most significant medical cannabis markets since March 2017, when the Gesetz zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften enabled physicians to prescribe cannabis to patients with serious conditions. The scale of uptake surpassed initial government projections: by 2023, prescription volumes were running into the hundreds of thousands annually, making Germany the largest medical cannabis market on the continent.

The Cannabis Act of 2024 delivered a structural change of considerable commercial importance. It removed cannabis-based medicinal products from the scope of the Narcotics Act (Betäubungsmittelgesetz, BtMG), eliminating the requirement for the special narcotic prescription form (BtM-Rezept). Physicians may now prescribe cannabis flower, extracts, and standardised preparations on a standard prescription, reducing administrative friction and — in principle — expanding the pool of prescribers willing to engage with the category.

Reimbursement through statutory health insurance (gesetzliche Krankenversicherung, GKV) applies where a prescribing physician determines that cannabis therapy is indicated, alternative treatments are not appropriate, and the patient is not participating in a clinical trial. Private health insurers have generally followed statutory reimbursement logic, though coverage terms vary. The BfArM administers the national cannabis agency and oversees quality standards for cultivated and imported medicinal product.

Import Dependency and Domestic Supply

Germany relies heavily on imported cannabis for its medical market, with supply originating primarily from Canada, the Netherlands, Portugal, and Denmark. Domestic cultivation licences were awarded by the BfArM through a competitive tender process, though production volumes from domestic growers remain a fraction of total market supply. Operators seeking to supply the German medical market must comply with European Union Good Manufacturing Practice (EU-GMP) standards — a prerequisite that has concentrated the supply chain among well-capitalised, licensed producers.

Adult Use and Possession Rules

The Cannabis Act introduced a framework for adult possession and personal cultivation that is, in global terms, progressive — but falls well short of the regulated commercial markets seen in Canada or several US states. The law establishes a clear possession threshold: adults aged 18 and over may carry up to 25 grammes in public without criminal liability. At home, the limit rises to 50 grammes.

These thresholds carry important caveats. The law prohibits possession within 100 metres of schools, children's daycare centres, sports facilities, and pedestrian zones during operating hours. Adults caught with quantities above the permitted thresholds face administrative or criminal penalties depending on the amount and circumstances. Consumption in the presence of minors and in vehicles remains prohibited.

Personal Cultivation

The CanG permits adults to cultivate up to three cannabis plants simultaneously for personal use. This provision reflects the government's attempt to divert consumer demand away from the unregulated black market without establishing a taxed retail supply chain. In practice, personal cultivation serves enthusiasts and patients seeking specific cultivar characteristics, rather than the mass market. There is no licence required for personal cultivation within the legal limits, though plants must be secured to prevent access by minors.

Cannabis Social Clubs (Anbauvereinigungen)

The Social Club model is the CanG's most commercially significant innovation. Registered non-profit associations — known formally as Anbauvereinigungen — may apply for licences to cultivate cannabis collectively for distribution to their members on a non-commercial basis. Key parameters include:

• Maximum membership: 500 adults (persons must be resident in Germany)
• Members may receive up to 25g per day, with a monthly cap of 50g (25g for adults aged 18 to 21)
• Clubs must operate without profit motive and invest any surplus back into the association
• Licensing is administered through state-level (Länder) competent authorities under federal framework rules
• Clubs must maintain records, implement youth-protection measures, and offer harm-reduction information

The Social Club framework launched in July 2024. Uptake in the first year was slower than anticipated, partly due to administrative complexity and uncertainty over local authority attitudes. Nevertheless, dozens of clubs received licences through 2025, and the model has attracted attention from investors and cannabis business operators seeking a compliant route to market in the interim period before commercial retail is authorised.

Business and Licensing Landscape

Germany's status as Europe's largest cannabis market by value — and its population of approximately 84 million — makes it the continent's most strategically significant jurisdiction for operators. However, the commercial opportunity remains constrained by the absence of adult-use retail licences.

The second legislative pillar of German cannabis reform, which would enable licensed commercial cultivation and retail sale, was under active discussion in the Bundestag through 2025. Regional pilot programmes in select cities were proposed as a mechanism to test commercial retail models under scientific supervision before any nationwide rollout. As of early 2026, no binding legislative timeline has been enacted, and the political environment remains fluid following federal elections.

For businesses, the immediate opportunities lie in the medical cannabis sector, Social Club servicing (equipment, legal compliance, genetics), and positioning ahead of an eventual commercial licensing regime. EU-GMP-certified producers continue to seek supply agreements with German distributors and pharmacies. The pharmacy channel — through which all medical cannabis is dispensed — represents a durable, regulated route to the consumer that has attracted significant interest from pharmaceutical-adjacent operators.

The German Federal Ministry of Health (Bundesgesundheitsministerium) publishes regulatory updates and guidance on the CanG framework. The BfArM handles licensing applications for medical cannabis cultivation and Social Club registrations at the federal level.

Penalties and Enforcement

The CanG decriminalised possession within defined thresholds, converting what was previously a criminal offence into an administrative infraction for quantities up to the legal limits. Possession above the threshold — or possession in a prohibited zone — can result in fines or, for significantly larger quantities, criminal prosecution. Supply and trafficking offences remain criminal, carrying custodial sentences.

German prosecutors retain discretion to apply the Opportunitätsprinzip (prosecutorial discretion) in marginal cases, and state-level approaches to enforcement have varied historically. However, the CanG creates a clearer national standard. Critically, the law included a provision enabling the expungement of prior convictions for conduct now lawful under the new framework — a significant step that affects tens of thousands of individuals with historical cannabis-related records.

Driving under the influence of cannabis remains prohibited. German road traffic law sets a THC blood serum limit (raised from the previously near-zero threshold to 3.5 nanograms per millilitre in 2024), aligning the standard more closely with evidence on impairment while acknowledging that residual THC from prior consumption should not constitute an automatic offence.

2026 Outlook

Germany enters 2026 at an inflection point. The first phase of the CanG — Social Clubs and personal possession — is operational, but the absence of commercial retail has left the country's enormous consumer market largely unserved by a legal supply chain. The black market, which analysts estimate turns over several billion euros annually, has contracted at the margins but remains substantial.

The political debate over the second legislative pillar is substantive. Proponents argue that regional pilot programmes would generate tax revenue, improve product safety, and further reduce criminal market activity. Opponents — including some state governments and medical associations — raise concerns about youth access and public health. The outcome of the 2025 federal elections introduced new variables into this calculus, and the trajectory of reform, while broadly intact, is subject to coalition dynamics.

For industry participants, the medium-term scenario most consistent with current political signals is a graduated expansion: pilot commercial retail in select cities within a three-to-five-year horizon, with potential nationwide rollout contingent on evaluation outcomes. Businesses that establish a presence now — through medical supply chains, Social Club engagement, or retail-adjacent services — are best positioned to scale when commercial licences become available.

Germany's reform has also reverberated across the European Union. Several member states have cited the German example in domestic policy debates. The five policy battles defining European cannabis in 2026 include the question of whether Germany's second pillar will crystallise — a decision that would reshape investment flows across the continent.